REG - OptiBiotix Health - Agreement with Weight Management Company

OptiBiotix HealthAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250820:nRST9607Va&default-theme=true

RNS Number : 9607V  OptiBiotix Health PLC  20 August 2025

OptiBiotix Health plc

("OptiBiotix" or the "Company" or "the Group")

 

Agreement with well-known Weight Management Company

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
products which reduce hunger and food cravings, enhance the gut microbiome,
and sweet fibres as healthy sugar substitutes announces the signing of a
distribution agreement with a well-known direct selling weight management
company (the "Distributor").

 

OptiBiotix will provide a range of SlimBiome® finished products under the
Distributor's own branding and a WellBiome® product which will be included in
their product range. The Distributor plans to launch in its biggest territory
by sales first, which, if successful, will be followed by subsequent launches
in other European countries. The products will be sold via a long standing and
established distribution channel of consultants and via e-commerce. As part of
this agreement, a first order is expected to be placed within the first three
months of signing the agreement.  Further information on the Distributor and
brand will be announced on launch which OptiBiotix anticipates will be in H1
2026.

 

This agreement reflects the interest OptiBiotix is seeing in bringing
functionality to weight management with traditional brands looking to leverage
the interest in products which reduce hunger and cravings generated by the
anti-obesity drugs. This agreement opens new opportunities to include science
backed functional ingredients into well-known weight management brands.

 

Stephen O'Hara, CEO of OptiBiotix Health plc said: "We are pleased to announce
this agreement with a well-known and established weight management company.
This agreement brings together the trust, loyalty, and customer base of a
recognised brand with the science and functionality of SlimBiome®.

 

"Following the launch of anti-obesity drugs, natural, scientifically proven,
non-drug alternatives to reduce hunger and cravings are actively being sought
by consumers. This announcement demonstrates that the science and multiple
human studies carried out on SlimBiome® is attracting the interest of major
brands around the world."

 

The Directors of the Company are responsible for the release of this
announcement.

 

For further information, please contact:

 

 For further information, please contact: OptiBiotix Health plc      www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman           Contact via Walbrook below
 Stephen O'Hara, Chief Executive

 Cairn Financial Advisers LLP (NOMAD and Broker)                     Tel: 020 7213 0880
 Liam Murray / Jo Turner / Ludovico Lazzaretti

 Walbrook PR Ltd                                                     Mob: 07876 741 001
 Anna Dunphy

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward
looking statements. Forward looking statements are identified by their use of
terms and phrases such as ''believe'', ''could'', "should" ''envisage'',
''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect",
''will'' or the negative of those, variations or comparable expressions,
including references to assumptions.  These forward looking statements are
not based on historical facts but rather on the Directors' current
expectations and assumptions regarding the Company's future growth, results of
operations, performance, future capital and other expenditures (including the
amount, nature and sources of funding thereof), competitive advantages,
business prospects and opportunities. Such forward looking statements reflect
the Directors' current beliefs and assumptions and are based on information
currently available to the Directors.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  AGRFZGMRKLMGKZM